I recommend waiting for a better discount before investing in IDEXX Laboratories Inc. (IDXX).

After finishing at $475.13 in the prior trading day, IDEXX Laboratories Inc. (NASDAQ: IDXX) closed at $488.88, up 2.89%. In other words, the price has increased by $+13.75 from its previous closing price. On the day, 562535 shares were traded. IDXX stock price reached its highest trading level at $491.07 during the session, while it also had its lowest trading level at $472.26.

Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored

Ratios:

Our goal is to gain a better understanding of IDXX by taking a closer look at its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 396.67 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 87.82. For the most recent quarter (mrq), Quick Ratio is recorded 0.60 and its Current Ratio is at 0.90. In the meantime, Its Debt-to-Equity ratio is 2.93 whereas as Long-Term Debt/Eq ratio is at 1.60.

Upgrades & Downgrades

On July 21, 2022, Goldman Upgraded its rating to Buy which previously was Neutral and also lowered its target price recommendation from $530 to $435.

On July 12, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $440.Piper Sandler initiated its Overweight rating on July 12, 2022, with a $440 target price.

Insider Transactions:

The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Dec 05 when JUNIUS DANIEL M sold 3,046 shares for $424.91 per share. The transaction valued at 1,294,276 led to the insider holds 2,968 shares of the business.

SZOSTAK M ANNE sold 740 shares of IDXX for $317,127 on Dec 02. The Director now owns 1,260 shares after completing the transaction at $428.55 per share. On Dec 01, another insider, Turner Kathy V, who serves as the Senior Vice President of the company, sold 3,000 shares for $436.00 each. As a result, the insider received 1,308,000 and left with 6,923 shares of the company.

Valuation Measures:

As of this moment, IDEXX’s Price-to-Earnings (P/E) ratio for their current fiscal year is 62.17, and their Forward P/E ratio for the next fiscal year is 51.94. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.59. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.78 while its Price-to-Book (P/B) ratio in mrq is 85.47.

Stock Price History:

Over the past 52 weeks, IDXX has reached a high of $574.33, while it has fallen to a 52-week low of $317.06. The 50-Day Moving Average of the stock is 426.73, while the 200-Day Moving Average is calculated to be 390.48.

Shares Statistics:

The stock has traded on average 495.17K shares per day over the past 3-months and 626.75k shares per day over the last 10 days, according to various share statistics. A total of 83.25M shares are outstanding, with a floating share count of 82.01M. Insiders hold about 0.30% of the company’s shares, while institutions hold 91.80% stake in the company. Shares short for IDXX as of Oct 13, 2022 were 2.37M with a Short Ratio of 2.11M, compared to 2.13M on Sep 14, 2022. Therefore, it implies a Short% of Shares Outstanding of 2.85% and a Short% of Float of 3.23%.

Earnings Estimates

Its stock is currently analyzed by 10 different market analysts. On average, analysts expect EPS of $2.04 for the current quarter, with a high estimate of $2.08 and a low estimate of $1.96, while EPS last year was $2.03. The consensus estimate for the next quarter is $2.01, with high estimates of $2.08 and low estimates of $1.95.

Analysts are recommending an EPS of between $8.81 and $7.78 for the fiscal current year, implying an average EPS of $7.95. EPS for the following year is $9.57, with 12 analysts recommending between $10.17 and $9.12.

Revenue Estimates

9 analysts predict $830.78M in revenue for the current quarter. It ranges from a high estimate of $837M to a low estimate of $826M. As of the current estimate, IDEXX Laboratories Inc.’s year-ago sales were $810.42M, an estimated increase of 2.50% from the year-ago figure. For the next quarter, 9 analysts are estimating revenue of $827.63M, an increase of 3.30% over than the figure of $2.50% in the same quarter last year. There is a high estimate of $844.08M for the next quarter, whereas the lowest estimate is $809M.

A total of 11 analysts have provided revenue estimates for IDXX’s current fiscal year. The highest revenue estimate was $3.48B, while the lowest revenue estimate was $3.33B, resulting in an average revenue estimate of $3.37B. In the same quarter a year ago, actual revenue was $3.22B, up 4.70% from the average estimate. Based on 11 analysts’ estimates, the company’s revenue will be $3.64B in the next fiscal year. The high estimate is $3.8B and the low estimate is $3.57B. The average revenue growth estimate for next year is up 8.10% from the average revenue estimate for this year.